IGC Pharma Inc
For the period ended Mar 31, 2024. Filed Jun 24, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Jun 24, 2024
IGC$0.20-4.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except loss per share and share data)
| Years Ended March 31, | ||||
|---|---|---|---|---|
| 2024 ($) | 2023 ($) | |||
| Revenue | 1,345 | 911 | ||
| Cost of revenue | (612) | (469) | ||
| Gross profit | 733 | 442 | ||
| Selling, general and administrative expenses | (6,758) | (8,552) | ||
| Research and development expenses | (3,773) | (3,461) | ||
| Operating loss | (9,798) | (11,571) | ||
| Impairment loss on PPE | (3,345) | - | ||
| Other income, net | 143 | 65 | ||
| Loss before income taxes | (13,000) | (11,506) | ||
| Income tax expense/benefit | - | - | ||
| Net loss attributable to common stockholders | (13,000) | (11,506) | ||
| Foreign currency translation adjustments | (34) | (421) | ||
| Comprehensive loss | (13,034) | (11,927) | ||
| Net loss per share attributable to common stockholders: | ||||
| Basic and diluted | $(0.22) | $(0.22) | ||
| Weighted-average number of shares used in computing loss per share amounts: | 58,839,868 | 52,576,258 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.